Corcept Therapeutics (NASDAQ:CORT) Insider William Guyer Sells 4,500 Shares of Stock

Corcept Therapeutics Incorporated (NASDAQ:CORT) insider William Guyer sold 4,500 shares of the stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $80.90, for a total transaction of $364,050.00. Following the sale, the insider owned 787 shares in the company, valued at approximately $63,668.30. The trade was a 85.11% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

William Guyer also recently made the following trade(s):

• On Wednesday, November 5th, William Guyer sold 20,000 shares of Corcept Therapeutics stock. The stock was sold at an average price of $75.36, for a total value of $1,507,200.00.
• On Tuesday, October 7th, William Guyer sold 20,000 shares of Corcept Therapeutics stock. The stock was sold at an average price of $89.94, for a total transaction of $1,798,800.00.
• On Tuesday, September 2nd, William Guyer sold 20,000 shares of Corcept Therapeutics stock. The shares were sold at an average price of $70.49, for a total transaction of $1,409,800.00.

Corcept Therapeutics Price Performance

NASDAQ CORT opened at $79.80 on Thursday. The business’s fifty day moving average price is $78.26 and its 200-day moving average price is $74.03. The stock has a market capitalization of $8.39 billion, a price-to-earnings ratio of 70.62 and a beta of 0.43. Corcept Therapeutics Incorporated has a 1-year low of $49.00 and a 1-year high of $117.33.

Corcept Therapeutics (NASDAQ:CORT) last posted its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $0.16 EPS for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.02). The firm had revenue of $207.64 million for the quarter, compared to analysts’ expectations of $223.78 million. Corcept Therapeutics had a net margin of 18.51% and a return on equity of 20.10%. The firm’s revenue was up 13.8% compared to the same quarter last year. During the same quarter last year, the company posted $0.41 EPS. Corcept Therapeutics has set its FY 2025 guidance at EPS. Equities research analysts anticipate that Corcept Therapeutics Incorporated will post 1.36 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts recently issued reports on CORT shares. Piper Sandler dropped their price objective on shares of Corcept Therapeutics from $131.00 to $121.00 and set an “overweight” rating on the stock in a report on Friday, August 1st. HC Wainwright reiterated a “buy” rating and set a $145.00 price target on shares of Corcept Therapeutics in a research note on Tuesday. Weiss Ratings reissued a “hold (c-)” rating on shares of Corcept Therapeutics in a research report on Wednesday, November 19th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $140.00 target price on shares of Corcept Therapeutics in a report on Thursday, September 25th. Finally, Wolfe Research assumed coverage on Corcept Therapeutics in a research report on Tuesday, November 18th. They set a “peer perform” rating on the stock. Four investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Corcept Therapeutics has a consensus rating of “Hold” and an average target price of $135.25.

Institutional Investors Weigh In On Corcept Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of CORT. Pathstone Holdings LLC grew its position in shares of Corcept Therapeutics by 0.8% during the third quarter. Pathstone Holdings LLC now owns 18,013 shares of the biotechnology company’s stock worth $1,497,000 after purchasing an additional 144 shares in the last quarter. Huntington National Bank boosted its stake in Corcept Therapeutics by 54.0% in the 2nd quarter. Huntington National Bank now owns 479 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 168 shares during the period. Focus Partners Wealth raised its position in shares of Corcept Therapeutics by 0.5% during the first quarter. Focus Partners Wealth now owns 33,243 shares of the biotechnology company’s stock valued at $3,797,000 after buying an additional 170 shares during the last quarter. Campbell Newman Asset Management Inc. lifted its holdings in shares of Corcept Therapeutics by 0.5% in the third quarter. Campbell Newman Asset Management Inc. now owns 35,530 shares of the biotechnology company’s stock worth $2,953,000 after buying an additional 170 shares in the last quarter. Finally, Nisa Investment Advisors LLC grew its stake in Corcept Therapeutics by 1.8% during the second quarter. Nisa Investment Advisors LLC now owns 9,951 shares of the biotechnology company’s stock valued at $730,000 after acquiring an additional 180 shares in the last quarter. 93.61% of the stock is owned by institutional investors.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.